Skip to content
Human-limitedDual GIP/GLP-1 receptor agonist

Tirzepatide

Dual GIP/GLP-1 agonist for superior weight loss & glycemic control.

Overview

Binds to GIP and GLP-1 receptors on pancreatic beta cells, brain, and gut to coordinate glucose and appetite regulation.

Proposed mechanism

Dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, delays gastric emptying, and promotes satiety.

What the evidence supports

Human data exists but the trials are small, short-term, or not yet replicated.

Graded Human-limited

Human data that exists but is thin: open-label work, single-arm studies, small cohorts, or observational follow-up without randomisation.

Key citations

Representative primary sources, including results that did not favour the compound.

  1. [1]

    Tirzepatide vs semaglutide (SURPASS-2)

    · DOI:10.1056/NEJMoa2107519 · 2021

  2. [2]

    SURMOUNT-1 weight loss

    · DOI:10.1056/NEJMoa2206038 · 2022

  3. [3]

    Tirzepatide vs semaglutide (SURPASS-2) (2021)

    · · 0

  4. [4]

    SURMOUNT-1 weight loss (2022)

    · · 0

Citation records in this build are illustrative placeholders for the design.

Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.